Middelburg J, Kemper K, Engelberts P, Labrijn AF, Schuurman J, van Hall T. Overcoming Challenges for CD3-Bispecific Antibody Therapy in Solid Tumors. Cancers (Basel). 2021 Jan 14;13(2):287. 来源:闲谈 Immunology2024-02-04
1、Kristine A. Frerichs, Marloes E.C. Broekmans, Jhon A. Marin Soto et al.Preclinical activity of JNJ-7957, a novel BCMAxCD3 bispecific antibodyfor the treatment of multiple myeloma, is potentiated by daratumumab.AACR2020 2、Kodandaram Pilla...
Shaohong Yin, Junyuan Qi. Results from a first-in-human phase I study of F182112, a B-cell maturation antigen (BCMA)-CD3 bispecific antibody, in patients with relapsed/refractory multiple myeloma. ASCO 2023 Abstract 8038
[3] Pfizer Initiates Pivotal Phase 2 MagnetisMM-3 Trial of BCMA-CD3 Bispecific Antibody Elranatamab (PF-06863135) in Multiple Myeloma. Retrieved Feb 17,2021,from https://www.pfizer.com/news/press-release/press-release-detail/pfizer-initiates-pivotal-phase-2-magnetismm-3-trial-bcma 本文来自药...
The invention relates to a bispecific antibody specifically binding to human B cell maturation antigen (BCMA) and to human CD3 (CD3) together with an immunotherapeutic drug for combined use in treating multiple myeloma.Minh Diem VuKlaus Strein...
2.Updated phase 1 results of teclistamab, a B-cell maturation antigen (BCMA) × CD3 bispecific antibody, in relapsed/refractory multiple myeloma (MM). fromhttps://meetinglibrary.asco.org/record/195433/abstract; 3.https://biopharma.media/tecvayli-new-drug-for-multiple-myeloma-5004/; ...
[1] Pan D, Richter J. Teclistamab for Multiple Myeloma: Clinical Insights and Practical Considerations for a First-in-Class Bispecific Antibody. Cancer Manag Res. 2023 Jul 21;15:741-751. doi: 10.2147/CMAR.S372237. PMID: 37497430; PMCID: PMC10368105. ...
1. Pfizer Presents First Data from Planned Interim Analysis of Pivotal Phase 2 MagnetisMM-3 Trial of BCMA-CD3 Bispecific Antibody Elranatamab Under Investigation for Relapsed/Refractory Multiple Myeloma | Pfizer 2. Teclistamab in Relapsed or Refractory Multiple Myeloma | NEJM...
A bispecific antibody specifically binding to the two targets human CD3ε and human BCMA, wherein the variable domains of one antibody portion are replaced by each other, and characterized in that the binding of said antibody is not reduced by APRIL and not reduced by BAFF, said antibody ...
[3]Updated phase 1 results of teclistamab, a B-cell maturation antigen (BCMA) × CD3 bispecific antibody, in relapsed/refractory multiple myeloma (MM). from https://meetinglibrary.asco.org/record/195433/abstract